DAX23.502 -1,0%Est505.737 -0,6%MSCI World4.343 -0,1%Top 10 Crypto9,6000 -3,8%Nas22.152 -1,5%Bitcoin62.054 -3,2%Euro1,1460 ±0,0%Öl107,4 +3,8%Gold4.833 -3,3%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 Siemens Energy ENER6Y DroneShield A2DMAA SAP 716460 Lufthansa 823212 Deutsche Telekom 555750 Commerzbank CBK100 Allianz 840400 Deutsche Bank 514000 Volkswagen (VW) vz. 766403 NEL ASA A0B733 Bayer BAY001 Infineon 623100 Shell (ex Royal Dutch Shell) A3C99G
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Fed lässt Leitzins stabil: DAX letztlich in Rot -- US-Börsen tiefer -- thyssenkrupp nucera: Großauftrag -- SAP, Siemens Energy, Rüstungsaktien, Droneshield, Commerzbank, NVIDIA im Fokus
Top News
Ausblick: Enel präsentiert Bilanzzahlen zum jüngsten Jahresviertel Ausblick: Enel präsentiert Bilanzzahlen zum jüngsten Jahresviertel
Ausblick: Schoeller-Bleckmann präsentiert Quartalsergebnisse Ausblick: Schoeller-Bleckmann präsentiert Quartalsergebnisse
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Addex Therapeutics Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
5,40 EUR -0,35 EUR -6,09 %
BMN
5,90 USD -0,10 USD -1,67 %
nachbörslich
BTT
finanzen.net zero
Addex Therapeutics jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone
KGV0,71Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA3EXC6

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS00654J2069

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolADXN

Addex Therapeutics Aktien News

DatumMeistgelesen
Dow JonesPress Release: Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Rel...
Dow JonesPress Release: Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia
Dow JonesPress Release: Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.
Wer­bungAddex Therapeutics-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
Dow JonesPress Release: Addex Therapeutics Reports 2025 -2-
Dow JonesPress Release: Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update
Dow JonesPress Release: Addex Therapeutics Reports 2025 -2-
Dow JonesPress Release: Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results and Provides Corporate Update
Dow JonesPress Release: Addex Appoints Bank of New York Mellon as Depositary Bank
Dow JonesPress Release: Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders
Dow JonesPress Release: Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update
Dow JonesPress Release: Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple Chronic Cough Preclinical Models
Dow JonesPress Release: Addex to Present Positive GABAB PAM Chronic Cough Data at the 10th American Cough Conference
Dow JonesPress Release: Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies
Dow JonesPress Release: Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain I...
Dow JonesPress Release: Addex Reports Full Year 2024 -2-
Dow JonesPress Release: Addex Reports Full Year 2024 Financial Results and Provides Corporate Update
Dow JonesPress Release: Addex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149
Dow JonesPress Release: Addex to Present at the 2025 Swiss Equities Baader Conference
Dow JonesPress Release: Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Dow JonesPress Release: Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024
Dow JonesPress Release: Addex Therapeutics Reports 2024 -2-
Dow JonesPress Release: Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update
Dow JonesPress Release: Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit
Dow JonesPress Release: Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration
Dow JonesPress Release: Addex's Partner Discontinues ADX71149 development in Epilepsy
Dow JonesPress Release: Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS)
Dow JonesPress Release: Addex To Present at the Thirteenth London International Cough Symposium (13th LICS)
Dow JonesPress Release: Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update
Dow JonesPress Release: Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
Dow JonesPress Release: Addex and Perceptive Launch -2-
Dow JonesPress Release: Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disor...
Dow JonesPress Release: Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.
Dow JonesPress Release: Addex to Present at the Swiss Equities Baader Conference
Dow JonesPress Release: Addex to Present at Biotech Showcase(TM) 2024
Dow JonesPress Release: Addex Reports Q3 2023 Financial -2-
Dow JonesPress Release: Addex Reports Q3 2023 Financial Results and Provides Corporate Update
Dow JonesPress Release: Addex Convenes Extraordinary General Meeting
Dow JonesPress Release: Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients
Dow JonesPress Release: Addex Announces Participation in the Bio-Europe 2023 Conference

Addex Therapeutics News

Addex Therapeutics News: auf dieser Seite finden Sie alle Addex Therapeutics News und Nachrichten zur Addex Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Addex Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Addex Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.